featured
Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2024 May 01;25(5)626-635, HA Burris, T Okusaka, A Vogel, MA Lee, H Takahashi, V Breder, JF Blanc, J Li, M Bachini, M Żotkiewicz, J Abraham, N Patel, J Wang, M Ali, N Rokutanda, G Cohen, DY OhFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.